OmicInsight

OmicInsight, based in the US and founded in the year 2024, provides advanced genomics solutions through its innovative Esper Platform, which enables precise single-cell analysis and supports significant advancements in biomedical research. OmicInsight specializes in genomics analytics, focusing primarily on single-cell analysis. The company is headquartered in Santa Clara, California, US. It raised venture funding on January 5, 2026, led by Lotte Holdings CVC, with participation from Adelphi Ventures.

OmicInsight specializes in advanced biomedical research through its flagship product, the Esper Platform. This platform integrates single-cell analysis with high-resolution imaging and AI-powered pipelines, enabling researchers to detect and quantify individual molecules within cells with high sensitivity. The focus is on enhancing understanding of cellular processes to advance personalized medicine. OmicInsight serves a diverse clientele that includes research institutions, pharmaceutical companies, and biotechnology firms across North America, Europe, and Asia.

By providing customizable analysis pipelines, the company ensures that insights generated are relevant and actionable, with the Esper Platform enhancing research accuracy through ultra-clear molecular imaging capabilities. OmicInsight generates revenue primarily through subscription-based models and partnerships within the biomedical research community. Clients engage with the company for access to the Esper Platform, which includes tiered subscription plans tailored to different research needs and budgets. This structure supports B2B transactions with institutional clients, such as universities and pharmaceutical companies, as well as collaborations with research organizations.

Pricing plans offer flexibility, allowing users to select from various service levels depending on their research requirements. As the company continues to innovate within the field of single-cell analysis, it strengthens its market position. In January 2026, OmicInsight raised venture funding, which will be utilized to expand its genomics analytics platform and support product development. The company is focused on launching new products designed to enhance its offerings and is actively targeting expansion into new markets, particularly in Europe and Asia, by the end of 2026.

The funding will facilitate these growth initiatives, allowing OmicInsight to further develop its technology and meet the evolving needs of its client base.